StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report issued on Thursday morning. The firm issued a sell rating on the medical technology company’s stock.
BIOLASE Stock Performance
Shares of NASDAQ:BIOL opened at $0.15 on Thursday. The firm’s 50 day moving average price is $0.17 and its 200-day moving average price is $0.88. The company has a current ratio of 1.26, a quick ratio of 0.68 and a debt-to-equity ratio of 34.06. BIOLASE has a twelve month low of $0.13 and a twelve month high of $47.10.
BIOLASE (NASDAQ:BIOL – Get Free Report) last issued its quarterly earnings results on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share for the quarter. The business had revenue of $13.49 million for the quarter. BIOLASE had a negative return on equity of 555.22% and a negative net margin of 41.97%.
Institutional Inflows and Outflows
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Stories
- Five stocks we like better than BIOLASE
- 3 Warren Buffett Stocks to Buy Now
- Comprehensive PepsiCo Stock Analysis
- What is Insider Trading? What You Can Learn from Insider Trading
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.